References
- Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2004;114:705–9.
- Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic telangiectasia. JAMA 1952;149:1376–80.
- Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010;120:432–5.
- Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219–29.
- Kell DL, Kamel OW, Rouse RV. Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue. Correlation of clones ER1D5 and 1A6 with a cytosol-based hormone receptor assay. Appl Immunohistochem 1993;1:275–81.
- Shi RS, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–8.
- Leong ASY,Milios J. Comparision of antibodies to estrogen and progesterone receptors and the influence of microwave-antigen retrieval. Appl Immunohistochem 1993;1:282–8.
- Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.] Pathologe 1987;8:138–40 (in German).
- Cerra Pohl A, Werner JA, Folz BJ. Screening for systemic manifestations of vascular malformations in patients with hereditary haemorrhagic telangiectasia (Osler disease). Acta Otorrinolaringol Esp 2008;59:463–8.
- Wehner LE, Folz BJ, Argyriou L, Twelkemeyer S, Teske U, Geisthoff UW, Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations. Clin Genet 2006;69:239–45.
- McCaffrey TV, Kern EB, Lake CF. Management of epistaxis in hereditary hemorrhagic telangiectasia: review of 80 cases. Arch Otolaryngol 1977;103:627–30.
- Van Custem E, Rutgeerts P, Van Trappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953–5.
- Haq AU, Glass J, Netchvolodoff CV, Bowen LM. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med 1988;109:171.
- Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009;119:284–8.
- Zacharski LR, Dunbar SD, Newsom WA Jr. Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia. Thromb Haemost 2001;85:371–2.
- Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabéu C, Botella LM. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010;103:525–34.
- Richtsmeier W, Weaver G, Streck W, Jacobson H, Dewell R, Olson J. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1984;92:564–70.
- Pau H, Carney AS, Walker R, Murty GE. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol Allied Sci 2000;25:547–50.
- Sadick H, Bergler WF, Oulmi-Kagermann J, Naim R, Sadick M, Hörmann K, Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res 2005;36:468–73.
- Zheng JW, Zhou Q, Yang XJ, Wang YA, Ye WM, Zhu HG, Anti-estrogenic agents might be more favorable option for treatment of hereditary hemorrhagic telangiectasia. Med Hypotheses 2009;72:230-1
- Duyka LJ, Fan CY, Coviello-Malle JM, Buckmiller L, Suen JY. Progesterone receptors identified in vascular malformations of the head and neck. Otolaryngol Head Neck Surg 2009;141:491–5.